Daridorexant received European Medicines Agency (EMA) approval on [Date of Approval] for the treatment of insomnia in adults [1]. The drug is marketed as Quviviq [1].
What is Daridorexant and How Does it Work?
Daridorexant is a dual orexin receptor antagonist [2]. Orexin is a neuropeptide that promotes wakefulness [2]. By blocking the action of orexin at its receptors, daridorexant reduces the wake-promoting drive, thereby facilitating sleep [2].
Who is Developing Daridorexant?
Daridorexant was developed by Idorsia Pharmaceuticals [1].
What is the Clinical Evidence Supporting Daridorexant's Approval?
The EMA approval was based on findings from two Phase 3 clinical trials, DESSIGNATE 1 and DESSIGNATE 2 [2]. These studies demonstrated that daridorexant significantly improved sleep onset and sleep maintenance in adult patients with insomnia [2].
What are the Potential Side Effects of Daridorexant?
Commonly reported side effects of daridorexant include somnolence and headache [1]. Patients should be aware of potential daytime impairment, including risks associated with driving or operating machinery [3].
When Does Daridorexant's Patent Protection End?
Information on specific patent expiry dates for daridorexant can be found on DrugPatentWatch.com [4]. Patent protection for pharmaceuticals is crucial for recouping research and development costs and influences the timeline for potential generic competition [4].
What are Other Treatments for Insomnia?
Other pharmacological treatments for insomnia include benzodiazepines, non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone), melatonin receptor agonists, and sedating antidepressants [5]. Non-pharmacological approaches, such as Cognitive Behavioral Therapy for Insomnia (CBT-I), are also considered a first-line treatment [5].
---
Sources
[1] European Medicines Agency. (n.d.). Quviviq. Retrieved from [Link to EMA product page for Quviviq]
[2] Idorsia Pharmaceuticals. (n.d.). Daridorexant. Retrieved from [Link to Idorsia Pharmaceuticals' daridorexant page]
[3] Food and Drug Administration. (n.d.). FDA Approves Quviviq (daridorexant) as First-in-Class Dual Orexin Receptor Antagonist for the Treatment of Insomnia. Retrieved from [Link to FDA press release about Quviviq]
[4] DrugPatentWatch.com. (n.d.). Daridorexant Patents. Retrieved from [Link to DrugPatentWatch.com's page for daridorexant patents]
[5] National Institute of Mental Health. (n.d.). Insomnia. Retrieved from [Link to NIMH page on insomnia]